1-6 of 6
Bruce D. Cheson
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Myeloablative vs nonmyeloablative consolidation for primary central nervous system lymphoma: results of Alliance 51101

Clinical Trials & Observations
Tracy T. Batchelor, Sharmila Giri, Amy S. Ruppert, Susan M. Geyer, Scott E. Smith, Nimish Mohile, Lode J. Swinnen, Jonathan W. Friedberg, Brad S. Kahl, Nancy L. Bartlett, Eric D. Hsi, Bruce D. Cheson, Nina Wagner-Johnston, Lakshmi Nayak, John P. Leonard, James L. Rubenstein
Journal: Blood Advances
Blood Adv (2024) 8 (12): 3189–3199.
https://doi.org/10.1182/bloodadvances.2023011657
Published: 2024
Includes: Supplemental data
Journal Articles

Impact of imaging frequency on progression-free survival in Alliance trials enrolling patients with follicular lymphoma

Clinical Trials & Observations
Sarah C. Rutherford, Jun Yin, Levi D. Pederson, Kristie A. Blum, Peter Martin, Sin-Ho Jung, Barbara Grant, Cara Rosenbaum, Bruce D. Cheson, Nancy L. Bartlett, Sumithra J. Mandrekar, John P. Leonard
Journal: Blood Advances
Blood Adv (2024) 8 (6): 1464–1468.
https://doi.org/10.1182/bloodadvances.2023012090
Published: 2024
Includes: Supplemental data
Journal Articles

Safety and efficacy of atezolizumab with rituximab and CHOP in previously untreated diffuse large B-cell lymphoma

Clinical Trials & Observations
Anas Younes, John M. Burke, Bruce D. Cheson, Catherine S. Diefenbach, Silvia Ferrari, Uwe H. Hahn, Eliza A. Hawkes, Cyrus Khan, Izidore S. Lossos, Gerardo Musuraca, Monica Tani, Umberto Vitolo, Sam Yuen, Aparna Raval, Mahesh Shivhare, Tina G. Nielsen, Gila Sellam, Jeff P. Sharman
Journal: Blood Advances
Blood Adv (2023) 7 (8): 1488–1495.
https://doi.org/10.1182/bloodadvances.2022008344
Published: 2023
Includes: Supplemental data
Journal Articles

Integrated safety analysis of umbralisib, a dual PI3Kδ/CK1ε inhibitor, in relapsed/refractory lymphoid malignancies

Clinical Trials & Observations
Matthew S. Davids, Owen A. O’Connor, Wojciech Jurczak, Felipe Samaniego, Timothy S. Fenske, Pier Luigi Zinzani, Manish R. Patel, Nilanjan Ghosh, Bruce D. Cheson, Enrico Derenzini, Danielle M. Brander, James A. Reeves, Wanda Knopińska-Posłuszny, John N. Allan, Tycel Phillips, Paolo F. Caimi, Ewa Lech-Maranda, John M. Burke, Richy Agajanian, Ruth Pettengell, Lori A. Leslie, Chan Y. Cheah, Gustavo Fonseca, James Essell, Julio C. Chavez, John M. Pagel, Jeff P. Sharman, Yanzhi Hsu, Hari P. Miskin, Peter Sportelli, Michael S. Weiss, Ian W. Flinn
Journal: Blood Advances
Blood Adv (2021) 5 (23): 5332–5343.
https://doi.org/10.1182/bloodadvances.2021005132
Published: 2021
Includes: Supplemental data
Journal Articles

A retrospective comparison of venetoclax alone or in combination with an anti-CD20 monoclonal antibody in R/R CLL

Clinical Trials & Observations
Anthony R. Mato, Lindsey E. Roeker, Toby A. Eyre, Chadi Nabhan, Nicole Lamanna, Brian T. Hill, Danielle M. Brander, Paul M. Barr, Frederick Lansigan, Bruce D. Cheson, Arun K. Singavi, Maryam Sarraf Yazdy, Nirav N. Shah, John N. Allan, Erica B. Bhavsar, Joanna Rhodes, Kaitlin Kennard, Stephen J. Schuster, AnnaLynn M. Williams, Alan P. Skarbnik, Andre H. Goy, Julie M. Goodfriend, Colleen Dorsey, Catherine C. Coombs, Hande Tuncer, Chaitra S. Ujjani, Ryan Jacobs, Allison M. Winter, John M. Pagel, Neil Bailey, Anna Schuh, Mazyar Shadman, Andrea Sitlinger, Hanna Weissbrot, Sivraj Muralikrishnan, Andrew Zelenetz, Amy A. Kirkwood, Christopher P. Fox
Journal: Blood Advances
Blood Adv (2019) 3 (10): 1568–1573.
https://doi.org/10.1182/bloodadvances.2019000180
Published: 2019
Journal Articles

A phase 1 study of lenalidomide and ibrutinib in combination with rituximab in relapsed and refractory CLL

Clinical Trials & Observations
Chaitra Ujjani, Hongkun Wang, Alan Skarbnik, Neel Trivedi, Pari Ramzi, Nadia Khan, Bruce D. Cheson
Journal: Blood Advances
Blood Adv (2018) 2 (7): 762–768.
https://doi.org/10.1182/bloodadvances.2017015263
Published: 2018